Division of General Internal Medicine, San Francisco VA Medical Center, University of California, San Francisco, CA, USA.
Am J Kidney Dis. 2012 Dec;60(6):922-9. doi: 10.1053/j.ajkd.2012.06.002. Epub 2012 Jul 17.
The primary aim of this study was to compare the sensitivity and rapidity of acute kidney injury (AKI) detection by cystatin C level relative to creatinine level after cardiac surgery.
Prospective cohort study.
SETTINGS & PARTICIPANTS: 1,150 high-risk adult cardiac surgery patients in the TRIBE-AKI (Translational Research Investigating Biomarker Endpoints for Acute Kidney Injury) Consortium.
Changes in serum creatinine and cystatin C levels.
Postsurgical incidence of AKI.
Serum creatinine and cystatin C were measured at the preoperative visit and daily on postoperative days 1-5. To allow comparisons between changes in creatinine and cystatin C levels, AKI end points were defined by the relative increases in each marker from baseline (25%, 50%, and 100%) and the incidence of AKI was compared based on each marker. Secondary aims were to compare clinical outcomes among patients defined as having AKI by cystatin C and/or creatinine levels.
Overall, serum creatinine level detected more cases of AKI than cystatin C level: 35% developed a ≥25% increase in serum creatinine level, whereas only 23% had a ≥25% increase in cystatin C level (P < 0.001). Creatinine level also had higher proportions meeting the 50% (14% and 8%; P < 0.001) and 100% (4% and 2%; P = 0.005) thresholds for AKI diagnosis. Clinical outcomes generally were not statistically different for AKI cases detected by creatinine or cystatin C level. However, for each AKI threshold, patients with AKI confirmed by both markers had a significantly higher risk of the combined mortality/dialysis outcome compared with patients with AKI detected by creatinine level alone (P = 0.002).
There were few adverse clinical outcomes, limiting our ability to detect differences in outcomes between subgroups of patients based on their definitions of AKI.
In this large multicenter study, we found that cystatin C level was less sensitive for AKI detection than creatinine level. However, confirmation by cystatin C level appeared to identify a subset of patients with AKI with a substantially higher risk of adverse outcomes.
本研究的主要目的是比较心脏手术后胱抑素 C 水平相对于肌酐水平检测急性肾损伤(AKI)的敏感性和速度。
前瞻性队列研究。
TRIBE-AKI(急性肾损伤生物标志物终点转化研究)联盟中的 1150 名高危成年心脏手术患者。
血清肌酐和胱抑素 C 水平的变化。
手术后 AKI 的发生率。
术前就诊时和术后第 1-5 天每天测量血清肌酐和胱抑素 C。为了允许比较肌酐和胱抑素 C 水平的变化,根据每个标志物从基线的相对增加(25%、50%和 100%)定义 AKI 终点,并根据每个标志物比较 AKI 的发生率。次要目标是比较根据胱抑素 C 和/或肌酐水平定义为 AKI 的患者的临床结局。
总的来说,血清肌酐水平比胱抑素 C 水平检测到更多的 AKI 病例:35%的患者血清肌酐水平升高≥25%,而只有 23%的患者胱抑素 C 水平升高≥25%(P < 0.001)。肌酐水平也有更高的比例符合 AKI 诊断的 50%(14%和 8%;P < 0.001)和 100%(4%和 2%;P = 0.005)阈值。对于通过肌酐或胱抑素 C 水平检测到的 AKI 病例,临床结局通常没有统计学差异。然而,对于每个 AKI 阈值,与仅通过肌酐水平检测到 AKI 的患者相比,通过两种标志物均确诊为 AKI 的患者的死亡率/透析联合结局风险显著更高(P = 0.002)。
不良临床结局较少,限制了我们根据 AKI 定义的不同,在患者亚组之间检测结局差异的能力。
在这项大型多中心研究中,我们发现胱抑素 C 水平对 AKI 的检测敏感性低于肌酐水平。然而,胱抑素 C 水平的确认似乎确定了一组 AKI 患者,他们的不良结局风险显著更高。